Sustained Virological Responses (SVR) of 97% in Genotype 2 (GT-2) Patients with F3/4 Stage of Fibrosis Treated with Sofosbuvir (SOF) and Weight-Based Ribavirin (RBV): A Real Life, Single Centre Experience